SCHEMBL3871546

SCHEMBL3871546

FOc1ccc2[nH]ccc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 4/20 0.55
NR4A2 P43354 2/20 0.50
LTA4H P09960 2/20 0.50
CYP2A6 P11509 2/20 0.50
F7 P08709 1/20 0.50
F3 P13726 1/20 0.50
USP2 O75604 1/20 0.50
GAA P10253 1/20 0.50
ALOX15 P16050 1/20 0.50
RAD51 Q06609 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
MAOA P21397 2/20 0.47
GPR84 Q9NQS5 1/20 0.47
IMPDH2 P12268 1/20 0.46
IMPDH1 P20839 1/20 0.46
MEN1 O00255 1/20 0.46
POLB P06746 1/20 0.46
MAPK1 P28482 1/20 0.46
KMT2A Q03164 1/20 0.46
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6970620 0.79 AHR (0.50) AHRNR4A2LTA4HCYP2A6F7
SCHEMBL29992449 0.79 MEN1 (0.71) AHRNR4A2LTA4HCYP2A6F7
SCHEMBL2426021 0.79 AHR (0.55) AHRNR4A2LTA4HCYP2A6F7
SCHEMBL74720 0.79 MEN1 (0.71) AHRNR4A2LTA4HCYP2A6F7
SCHEMBL4952881 0.79 AHR (0.55) AHRNR4A2LTA4HCYP2A6F7
SCHEMBL25462527 0.79 AHR (0.50) AHRNR4A2LTA4HCYP2A6F7
SCHEMBL1196876 0.79 ABL1 (0.52) AHRNR4A2LTA4HCYP2A6F7
SCHEMBL593378 0.79 AHR (0.50) AHRNR4A2LTA4HCYP2A6F7
SCHEMBL417223 0.78 AHR (0.48) AHRNR4A2LTA4HCYP2A6F7
Ammonia Solution, Strong SCHEMBL28589598 0.78 MEN1 (0.69) AHRNR4A2LTA4HCYP2A6F7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612389-B2 Benzofuran-based N-acylhydrazone derivative and pharmaceutical composition comprising same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2026-04-28 US disclosed
US-20230293487-A1 ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2023-09-21 US disclosed
EP-4186503-A1 ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES Korea Research Institute of Bioscience and Biotechnology (KR) 2023-05-31 EP disclosed
US-20220306612-A1 BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTEHNOLOGY (KR) 2022-09-29 US disclosed
EP-4015516-A1 BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Korea Research Institute of Bioscience and Biotechnology (KR) 2022-06-22 EP disclosed
CN-114206857-A Benzofuranyl N-acylhydrazone derivatives and pharmaceutical compositions containing the same 韩国生命工学研究院 2022-03-18 CN disclosed
WO-2022019663-A1 ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES 한국생명공학연구원 2022-01-27 WO disclosed
JP-2009040790-A PROCESS FOR PREPARING 5-FLUOROOXYINDOLE UBE IND LTD 2009-02-26 JP disclosed
EP-1310486-A4 PROCESS FOR PRODUCING 5-FLUOROOXYINDOLE AND FOR PRODUCING INTERMEDIATE THEREFOR UBE INDUSTRIES (JP) 2005-07-27 EP disclosed
US-20030181731-A1 Process for producing 5-fluorooxyindole and for producing intermediates therefor UBE INDUSTRIES., LTD (JP) 2003-09-25 US disclosed
JP-2002128761-A METHOD FOR PRODUCING 5-FLUOROOXYINDOLE UBE IND LTD 2002-05-09 JP disclosed
WO-2002006228-A1 PROCESS FOR PRODUCING 5-FLUOROOXYINDOLE AND FOR PRODUCING INTERMEDIATE THEREFOR UBE INDUSTRIES, LTD. (JP) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306612-A1 BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME NDUFAB1, BPTF, HDAC6 AHR 151/4885NR4A2 687/4885LTA4H 3178/4885
US-20230293487-A1 ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES RELA, NFKBIA, IKBKG AHR 244/4885NR4A2 155/4885LTA4H 1247/4885
US-12612389-B2 Benzofuran-based N-acylhydrazone derivative and pharmaceutical composition comprising same TUBB3, TUBA1C, ACIN1 AHR 811/4885NR4A2 1886/4885LTA4H 4418/4885
US-20030181731-A1 Process for producing 5-fluorooxyindole and for producing intermediates therefor FAR1, CYP4F11, FDPS AHR 476/4885NR4A2 2594/4885LTA4H 970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.